Sulbactam/durlobactam
| Combination of | |
|---|---|
| Sulbactam | beta-lactam antibacterial, beta-lactamase inhibitor |
| Durlobactam | beta-lactamase inhibitor |
| Clinical data | |
| Trade names | Xacduro |
| License data | |
| Routes of administration | Intravenous |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Sulbactam/durlobactam, sold under the brand name Xacduro (by Innoviva Specialty Therapeutics), is a co-packaged medication used for the treatment of bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex.[1][2] It contains sulbactam, a beta-lactam antibacterial and beta-lactamase inhibitor; and durlobactam, a beta-lactamase inhibitor.[1][2]
Sulbactam/durlobactam was approved for medical use in the United States in May 2023.[1][2]
- ^ a b c d "Xacduro- sulbactam and durlobactam kit". DailyMed. 2 June 2023. Retrieved 25 June 2023.
- ^ a b c "FDA Approves New Treatment for Pneumonia Caused by Certain Difficult-to-Treat Bacteria". U.S. Food and Drug Administration (Press release). 24 May 2023. Archived from the original on 23 May 2023. Retrieved 24 May 2023. This article incorporates text from this source, which is in the public domain.